Blog

Organon acquires two Eli Lilly migraine treatments, expanding its women’s health portfolio in Europe while Arcutis wins FDA approval for a foam skin treatment for seborrheic dermatitis. FDA also finalizes safety labeling changes for opioid-based medications. The biotech firm Atara Biotherapeutics will lay off 73 employees, and Akili’s ADHD video game treatment receives expanded FDA authorization. In the field of rare diseases, Sanofi and Boehringer invest $80M for a new study led by a veteran VC.

Explore the latest updates in the biopharmaceutical sector: disappointing prostate cancer study results from Point Biopharma, promising Covid-19 Phase III data from Invivyd triggers a stock soar, launch of Novo Nordisk’s whopping $260M vaccine initiative, and more. Your one-stop source for current biopharma news.

Explore the latest trends in the biotech sector, understand the impact of changing market dynamics, and discover strategic insights for pharma executives.

Here are the top stories for Friday, December 15, 2023. Nassim Usman, New CEO of Totus Medicines Totus Medicines has announced the closure of a

Biopharma news today includes Moderna’s chief commercial officer, Arpa Garay, leaving amidst a decrease in Covid sales. The House passed a bill targeting healthcare industry transparency, while Novo Nordisk fights CMS guidance. A new FDA committee will assess genetic metabolic disease treatments. J&J, Genmab, AbbVie, Roche, and Dizal made advances in cancer therapeutics, with potential medicine shortages in Europe, and GSK’s efforts to expand adult vaccine access.